ARCHIVES

Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML

This article is from The Cancer Letter archive.

Vol. 30 No. 12 | December 28, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Three, Perhaps Four May Be Recommended To Carter; Hugh Creech To Retire July 1

April 1, 1977

FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response

July 29, 2011

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

NIH Draft Guidelines On Stem Cell Research Limit Funds To Cells From In Vitro Fertilization

April 24, 2009

NCI Plans To Expand CTSU Management Of Clinical Trials.

February 24, 2006

Von Eschenbach Presents His “2015 Goal” As Logical Progression of Cancer Program (Interview)

May 16, 2003